الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and represents a major global public health challenge. It is characterised by the increased accumulation of hepatic fat (>5%) and is closely linked with the presence of the metabolic syndrome and its components: obesity, type 2 diabetes mellitus, hypertension and dyslipidaemia.
NAFLD is a spectrum of progressive liver disease comprising steatosis (non-alcoholic fatty liver, NAFL), in which excessive hepatic fat is present, and non-alcoholic steatohepatitis (NASH), a necroinflammatory form of the condition marked by histological inflammation and hepatocyte ballooning that leads to progressive liver fibrosis. NAFLD is a cause of significant morbidity and mortality; left untreated, fibrosis may progress to cirrhosis and can result in end-stage liver disease or hepatocellular carcinoma (HCC).
Several epidemiological studies indicate that NAFLD, especially in its more severe forms, is linked to an increased risk of cardiovascular disease, and this increased risk is independent from underlying cardio-metabolic risk factors.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is produced by inflammatory cells, co-travels with circulating low-density lipoprotein (LDL), and hydrolyzes oxidized phospholipids in LDL.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) was recently characterized as a novel vascular-specific inflammatory biomarker correlated with several components constituting the metabolic syndrome and implicated in atherosclerosis and incident cardiovascular disease. Some studies have demonstrated that lipoprotein-associated phospholipase A2 (Lp-PLA2), which was named firstly as platelet-activating factor acetylhydrolase (PAF-AH), is significantly associated with CVD.
The study is aimed to study serum levels of Lp-PLA2 in patients with NAFLD to detect its relation to the incidence and severity of NAFLD.
This is Case Control cross -sectional clinical Study, was carried out at Internal Medicine and Hepatology outpatient clinic at Ain Shams University Hospital on 80 persons were divided into 2 groups: (Group-I): 40 patient with NAFLD as a study group, (Group-II): Forty(40) healthy subjects as a control group.
The main results of the study revealed that:
There was statistically significant difference between the studied groups as regard Diabetes.
There was high statistically significant difference between the studied groups as regard weight, BMI and waist circumference.
There was high statistically significant difference between the studied groups as regard CRP, Platelets, Hb, FBG, Homa-IR and HbA1C.
There was high statistically significant difference between the studied groups as regard triglycerides and LDL and statistically significant difference as regard total cholesterol.
There was high statistically significant difference between the studied groups as regard Liver and kidney function.
There was high statistically significant difference between the studied groups as regard Lp-PLA2.
There was statistically significant difference between the studied groups as regard NAFLD Fibrosis Score.
Among the studied cases with significant NFS there were 4 (50%) F0, 1 (12.5%) F1, 1 (12.5%) F2 and 2 (25%) F3.
There was high statistically significant difference between the studied groups as regard Size.
Based on our results we recommend for further studies on larger patients and longer period of follow up to emphasize our conclusion.